The Department of Medicine
William B. Smith, MD
Professor
Division of Cardiology
Education
Medical School
Universidad Autonoma de Guadalajara
Residency
Internal Medicine, University of Tennessee Medical Center
Fellowship
Cardiology, Tulane University Medical Center and Affiliated Hospitals, New Orleans, LA
Nephrology, Vanderbilt University, Nashville, TN
Certifications
American Board of Internal Medicine
American Board of Internal Medicine - Cardiovascular Disease
American Board of Internal Medicine - Nephrology
Current Publications
Dowell JA, Marbury TC, Smith WB, Henkel T.
Safety and pharmacokinetics of taniborbactam (VNRX-5133) with cefepime in subjects with various degrees of renal impairment. Antimicrob Agents Chemother. 2022 Aug 3:e0025322. doi: 10.1128/aac.00253-22. Online ahead of print.
Dowell JA, Marbury TC, Smith WB, Henkel T.
Safety and pharmacokinetics of taniborbactam (VNRX-5133) with cefepime in subjects with various degrees of renal impairment. Antimicrob Agents Chemother. 2022 Aug 3:e0025322. doi: 10.1128/aac.00253-22. Online ahead of print.
Harrison SA, Manghi FP, Smith WB, Alpenidze D, Aizenberg D, Klarenbeek N, Chen CY, Zuckerman E, et al.
Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study. Nat Med. 2022 Jul;28(7):1432-1438. doi: 10.1038/s41591-022-01861-9. Epub 2022 Jun 20.
Harrison SA, Manghi FP, Smith WB, Alpenidze D, Aizenberg D, Klarenbeek N, Chen CY, Zuckerman E, et al.
Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study. Nat Med. 2022 Jul;28(7):1432-1438. doi: 10.1038/s41591-022-01861-9. Epub 2022 Jun 20.
Xu Y, Izumi R, Nguyen H, Kwan A, Kuo H, Madere J, Slatter JG, Podoll T, Vishwanathan K, Marbury T, Smith W, Preston RA, Sharma S, Ware JA.
Evaluation of the pharmacokinetics and safety of a single dose of acalabrutinib in subjects with hepatic impairment. J Clin Pharmacol. 2022 Jun;62(6):812-822. doi: 10.1002/jcph.2013. Epub 2022 Feb 15.
Xu Y, Izumi R, Nguyen H, Kwan A, Kuo H, Madere J, Slatter JG, Podoll T, Vishwanathan K, Marbury T, Smith W, Preston RA, Sharma S, Ware JA.
Evaluation of the pharmacokinetics and safety of a single dose of acalabrutinib in subjects with hepatic impairment. J Clin Pharmacol. 2022 Jun;62(6):812-822. doi: 10.1002/jcph.2013. Epub 2022 Feb 15.
Ayalon G, Lee SH, Adolfsson O, Foo-Atkins C, Atwal JK, Blendstrup M, Booler H, Bravo J, Brendza R, Brunstein F, Chan R, Chandra P, Couch JA, Datwani A, Demeule B, DiCara D, Erickson R, Ernst JA, Foreman O, He D, Hötzel I, Keeley M, Kwok MCM, Lafrance-Vanasse J, Lin H, Lu Y, Luk W, Manser P, Muhs A, Ngu H, Pfeifer A, Pihlgren M, Rao GK, Scearce-Levie K, Schauer SP, Smith WB, Solanoy H, Teng E, Wildsmith KR, Bumbaca Yadav D, Ying Y, Fuji RN, Kerchner GA.
Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease. Science Translational Medicine. 2021 May 12;13(593):eabb2639.